Disclosed is a method of treating Parkinsons disease and/or depression, and motor symptoms, non motor symptoms and depression symptoms associated with Parkinsons disease in a subject in need thereof, the method including administering to said subject a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof, wherein the administering is effected by intranasal administration, and wherein a daily dose of the rasagiline or pharmaceutically acceptable salt thereof in the pharmaceutical composition is sufficient to inhibit monoamine oxidase (MAO)-A and MAO-B in a brain but insufficient to inhibit systemic MAO-A and therefore does not potentiate sympathetic cardiovascular activity associated with tyramine rich food consuming. Also, disclosed is a pharmaceutical composition including rasagiline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, and a device configured for intranasal administration of a pharmaceutical composition including rasagiline or a pharmaceutically acceptable salt thereof to a subject.
